Extraordinary Cases of VTE Prevention in Patients With Cancer

Slides:



Advertisements
Similar presentations
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer Agnes Y. Y. Lee, MD, MSc; Pieter W. Kamphuisen, MD,
Advertisements

Addressing the Challenges in Primary and Secondary Stroke Prevention
Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.
Burden of Atrial Fibrillation The Percentage of Strokes Attributable to AF Increases With Age.
NOACs for Cancer-Associated Thrombosis:
Managing Bleeds in Patients Anticoagulated With Warfarin and Other Agents.
NOACs In Long-term VTE Treatment: A State Of The Art Review
Long-Term Treatment of VTE: Case Studies
US Guidelines US Guidelines Low-risk Patients.
Thrombosis, Cancer, and NOACs
The ABCs of AF.
Access to NOAC Therapy:
NOACs in Clinical Practice: Are They All the Same?
Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.
New Strategies to Prevent CV Events After Hospital Discharge
Emergency Management of NOAC Bleeding
A New Era for NOACs:.
Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy.
Anticoagulation Highlights From the American Heart Association Meeting 2017.
Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.
Through Thick and Thin.
What Has Been Tried and What Is True?
Oral Anticoagulants in AFa,b A Brief History.
Global Burden of VTE. Preventing Thrombosis During and Post-Hospitalization: New Paradigms in Clinical Care.
Surveying the Safety of NOACs in the Real World
Selecting NOACs for High-Risk Patients
A Case Challenge: Anticoagulant Choices for Acute PE
Antiplatelet Therapy and Secondary Prevention
NOAC Use in AF: REAL-WORLD Studies WITH REAL RESULTS
New Oral Anticoagulants and VTE Management
Real-World Safety of NOACs: What Do We Know Today?
VTE Treatment Conventional Approach
Applying Real-World Evidence in Atrial Fibrillation Into Clinical Care:
AF and PCI in Practice.
Access to NOAC Therapy:
Learning Objectives Classification of VTE Goals of VTE Treatment.
A Better Solution For Cancer Patients With VTE?
VTE in Cancer.
Reversal Strategies for VKA: Truths and Misconceptions
Oral Anticoagulation in AF
Real-World Evidence in VTE
Dos and Don’ts for High-Risk Elderly Patients With AF
Extending Treatment for Thrombosis: What’s the Right Choice?
Practical Considerations to Extend Treatment for VTE
Treatment of Thromboembolic Disease The Need for Multiple Perspectives
Anticoagulation and Thrombosis Management
Aspirin and Cardioprevention in 2018
Trials and Tribulations in VTE: How Do Real-World Data Fit In?
Long-Term Treatment of VTE: Case Studies
A Time for Change for Managing Patients With VTE Who Have Cancer
Cancer-Associated Thrombosis
Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?
Managing Pulmonary Embolism Posthospital Discharge
NOAC Studies in VTE AF Studies Superior Outcomes.
Extraordinary Cases in VTE
Program Goals Background: Anticoagulation in Patients With VTE.
Elevated Admission Plasma Glucose Following ACS
Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.
An Unmet Need.
Disease Burden of VTE Phases of VTE Treatment.
At the Crossroads of Coagulation
VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.
Omega-3s vs Pure EPA in Clinical Practice
Antiarrhythmic Drugs in AF
Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.
The Power of As-Treated Analyses
Antithrombotic Therapy in AF Patients Undergoing PCI
What's New in NOACs in AF?.
Treating Pulmonary Embolism Today
Can the Dual vs Triple Therapy Controversy in Patients With AF Undergoing PCI Be Put to Rest?
Presentation transcript:

Extraordinary Cases of VTE Prevention in Patients With Cancer

Patient Case

Risks of Cancer-Associated PE

CLOT A Landmark Study for Treatment of Cancer-Associated Thrombosis

Hokusai-VTE Cancer Study Design

Hokusai VTE-Cancer Primary Endpoint

Risk of Recurrent VTE in Cancer

SELECT-D Study Design

SELECT-D Efficacy and Safety

Dose Reduction in NOAC Trials

Clinical Implications of Hokusai VTE-Cancer and SELECT-D

Sites of Major Bleeding

Use of NOACs in Cancer-Associated VTE Considerations for GI Tract

US Prescription Patterns for Cancer-Associated VTE

Cost Considerations for VTE prevention

Anticoagulation and Cancer Recurrence Implications for Surgical interventions

Abbreviations